Expert opinion on pharmacotherapy
-
Expert Opin Pharmacother · Apr 2008
Review Comparative StudyHomoharringtonine for the treatment of chronic myelogenous leukemia.
The anticancer activity of the natural alkaloid homoharringtonine (HHT) was first recognized by Chinese investigators. HHT exerts its activity through inhibition of protein synthesis and promotion of apoptosis. ⋯ These encouraging results have propelled the development of several Phase II/III trials both in Europe and in the US to further delineate the activity of omacetaxine mepesuccinate in patients with CML who are resistant to TKI therapy.
-
Severe injury is often associated with haemorrhagic shock and this is the most common cause of preventable mortality after injury. Care of the injured patient in shock involves an overlapping continuum of care beginning during the prehospital phase of care and extending through the interventional and critical care phases. ⋯ Although the mainstay of therapy continues to be obtaining haemostasis and restoring tissue perfusion, a multitude of novel strategies are emerging, including advanced haemostatic agents, hypertonic resuscitation and massive transfusion protocols, as well as blood substitutes and an improved understanding of damage control principles, thereby allowing increased survival and improved outcomes in the severely injured patient with major haemorrhage.
-
Expert Opin Pharmacother · Apr 2008
ReviewPharmacotherapy of atrial fibrillation: an old option with new possibilities.
Atrial fibrillation is the most common sustained arrhythmia observed worldwide. Despite modern ablative treatment options, pharmacotherapy remains the first-line therapy in patients with atrial fibrillation. ⋯ The mainstay of atrial fibrillation therapy is the prevention of thromboembolic events. With growing knowledge of the pathophysiology of atrial fibrillation new drug targets have been identified that promise improved outcomes in atrial fibrillation management and this will allow individual drug treatment in the near future.
-
Expert Opin Pharmacother · Apr 2008
Comparative StudyLipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
To compare change in low-density lipoprotein cholesterol (LDL-C) levels and National Cholesterol Education Program (NCEP) Adult Treatment Panel III LDL-C goal attainment in diabetic patients treated with rosuvastatin versus other statins in a large, managed care health plan. ⋯ For diabetic patients, rosuvastatin is more effective at reducing LDL-C levels and attaining NCEP ATP III LDL-C goal than other statins in real-world clinical practice.